P-143: Breakthrough – a designated pharmacist in the hemato-oncology department improves both quality and sequence of drug treatment and reduces ADR in Multiple Myeloma patients during Covid-19 pandemic

BACKGROUND: In March 2020, COVID19 break out and since then the world has been facing a new reality. Multiple Myeloma patients due to their disease and chemotherapy were considered as a high-risk group for infection. Since then, in an attempt to avoid multiple exposures, encounters between patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Alabbasi, Areen, Cohen, Shai, Green, Manfred, Brammli, Shuli, Preis, Meir, Khalaily, Rasmieh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Poster Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580187/
http://dx.doi.org/10.1016/S2152-2650(21)02270-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580187/
http://dx.doi.org/10.1016/S2152-2650(21)02270-9

Ejemplares similares